Inogen, Inc. (NASDAQ:INGN) Shares Acquired by Barclays PLC

Barclays PLC increased its holdings in Inogen, Inc. (NASDAQ:INGN) by 72.9% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 55,508 shares of the medical technology company’s stock after purchasing an additional 23,398 shares during the quarter. Barclays PLC’s holdings in Inogen were worth $539,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the business. Meeder Asset Management Inc. acquired a new stake in shares of Inogen in the 2nd quarter worth approximately $30,000. Quarry LP bought a new stake in Inogen during the third quarter worth approximately $59,000. Verition Fund Management LLC bought a new stake in Inogen during the third quarter worth approximately $106,000. Paloma Partners Management Co acquired a new stake in Inogen in the third quarter worth approximately $126,000. Finally, Centiva Capital LP bought a new position in Inogen during the 3rd quarter valued at $138,000. 89.94% of the stock is currently owned by institutional investors and hedge funds.

Inogen Stock Performance

Shares of NASDAQ:INGN opened at $9.19 on Friday. The stock has a market capitalization of $218.89 million, a price-to-earnings ratio of -4.08 and a beta of 1.02. Inogen, Inc. has a 1-year low of $5.08 and a 1-year high of $13.33. The company has a 50 day moving average price of $9.38 and a 200 day moving average price of $9.76.

Wall Street Analyst Weigh In

A number of research firms have recently commented on INGN. StockNews.com downgraded Inogen from a “buy” rating to a “hold” rating in a research note on Friday, December 20th. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a research report on Friday, November 8th.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.